Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of RC017 Ophthalmic Ointment in Healthy Adults
NCT07521748Phase 1Not yet recruiting
- Sponsor
- Reju Therapeutics
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in dry eye disease (DED) comparing RC017 Ophthalmic Ointment with RC017 Ophthalmic Ointment placebo (2 arms). Primary endpoints: Incidence of Treatment-emergent adverse events, Severity of Treatment-emergent adverse events and 5 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
RC017
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07521748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07521748.